These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

613 related items for PubMed ID: 24018587

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Botulinum toxin for masseter hypertrophy.
    Al-Muharraqi MA, Fedorowicz Z, Al Bareeq J, Al Bareeq R, Nasser M.
    Cochrane Database Syst Rev; 2009 Jan 21; (1):CD007510. PubMed ID: 19160335
    [Abstract] [Full Text] [Related]

  • 3. Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases.
    Baş B, Ozan B, Muğlali M, Celebi N.
    Med Oral Patol Oral Cir Bucal; 2010 Jul 01; 15(4):e649-52. PubMed ID: 20173718
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type A therapy for cervical dystonia.
    Rodrigues FB, Duarte GS, Marques RE, Castelão M, Ferreira J, Sampaio C, Moore AP, Costa J.
    Cochrane Database Syst Rev; 2020 Nov 12; 11(11):CD003633. PubMed ID: 33180963
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type A therapy for cervical dystonia.
    Castelão M, Marques RE, Duarte GS, Rodrigues FB, Ferreira J, Sampaio C, Moore AP, Costa J.
    Cochrane Database Syst Rev; 2017 Dec 12; 12(12):CD003633. PubMed ID: 29230798
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin for myofascial pain syndromes in adults.
    Soares A, Andriolo RB, Atallah AN, da Silva EM.
    Cochrane Database Syst Rev; 2012 Apr 18; (4):CD007533. PubMed ID: 22513950
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
    Duarte GS, Castelão M, Rodrigues FB, Marques RE, Ferreira J, Sampaio C, Moore AP, Costa J.
    Cochrane Database Syst Rev; 2016 Oct 26; 10(10):CD004314. PubMed ID: 27782297
    [Abstract] [Full Text] [Related]

  • 9. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment.
    Xie Y, Zhou J, Li H, Cheng C, Herrler T, Li Q.
    Plast Reconstr Surg; 2014 Aug 26; 134(2):209e-218e. PubMed ID: 25068343
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Botulinum Toxin Injections for Masseter Reduction in East Asians.
    Cheng J, Hsu SH, McGee JS.
    Dermatol Surg; 2019 Apr 26; 45(4):566-572. PubMed ID: 30883483
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin type A treatment for contouring of the lower face.
    Park MY, Ahn KY, Jung DS.
    Dermatol Surg; 2003 May 26; 29(5):477-83; discussion 483. PubMed ID: 12752514
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy.
    Yeh YT, Peng JH, Peng HP.
    J Cosmet Dermatol; 2018 Oct 26; 17(5):675-687. PubMed ID: 30091170
    [Abstract] [Full Text] [Related]

  • 17. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients.
    Lee SH, Wee SH, Kim HJ, Yeo UC, Lee NH, Lee SW, Cho SB.
    J Dermatolog Treat; 2013 Apr 26; 24(2):133-6. PubMed ID: 21888570
    [Abstract] [Full Text] [Related]

  • 18. Use of botulinum toxin type A for the treatment of masseteric muscle hypertrophy.
    Arikan OK, Tan FU, Kendi T, Koc C.
    J Otolaryngol; 2006 Feb 26; 35(1):40-3. PubMed ID: 16527016
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.